UP421 / Sana Biotech - LARVOL DELTA

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire) - "Type 1 Diabetes – Sana continues the clinical development of gene-modified primary islet cells (UP421) and the pre-clinical development of SC451...Sana expects to share additional data in 2025 and file an IND as early as 2026....Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025....in vivo CAR T cells: Sana expects to file an IND for SG299 as early as 2026, and we look forward to developing it in a range of B-cell cancers and B-cell mediated autoimmune diseases."

Clinical data • IND • P1 data • ANCA Vasculitis • Immunology • Oncology • Systemic Lupus Erythematosus • Type 1 Diabetes Mellitus

First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=2 | Recruiting | Sponsor: Per-Ola Carlsson | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Transplantation • Type 1 Diabetes Mellitus